Skip to main content


Fig. 3 | BMC Pharmacology and Toxicology

Fig. 3

From: Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients

Fig. 3

BPI scores and Lyso-Gb3 levels. Using the BPI scores, pain in 14 patients who had a maximum pain of ≥3.0 units at BL improved (a) and pain in 16 patients who had an average pain of ≥1.0 units at BL also improved during the ERT period (b). The plasma Gb3 (c) and Lyso-Gb3 (d) levels were considered as the biomarker of FD and they were markedly decreased particularly in male patients

Back to article page